Phenotype and prognostic correlations of the converter region mutations affecting the β myosin heavy chain

Heart

Volumn 101, Issue 13, 2015, Pages 1047-1053

  García Giustiniani, Diego ^a   Arad, Michael ^b   Ortíz Genga, Martín ^a   Barriales Villa, Roberto ^c,d   Fernández, Xusto ^d   Rodríguez García, Isabel ^c   Mazzanti, Andrea ^a   Veira, Elena ^a   Maneiro, Emilia ^a   Rebolo, Paula ^a   Lesende, Iván ^a   Cazón, Laura ^d   Freimark, Dov ^b   Gimeno Blanes, Juan Ramón ^e   Seidman, Christine ^f   Seidman, Jonathan ^f   McKenna, William ^g   Monserrat, Lorenzo ^a,c  

^a Health in Code   (Spain)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF A CORUÑA   (Spain)

^d Red de Investigación Cardiovascular RIC   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARAGINE; GLUTAMINE; GLYCINE; ISOLEUCINE; MYOSIN HEAVY CHAIN BETA; CARDIAC MYOSIN; MYH7 PROTEIN, HUMAN; MYOSIN HEAVY CHAIN;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOMYOPATHY; CHILD; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HEART GRAFT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MYH7 GENE; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; RESTRICTIVE CARDIOMYOPATHY; SUDDEN CARDIAC DEATH; SURVIVAL RATE; SURVIVAL TIME; VENTRICULAR NONCOMPACTION; CARDIOMYOPATHIES; CLASSIFICATION; ECHOCARDIOGRAPHY; GENETICS; MIDDLE AGED; MUTATION; PEDIGREE; PROCEDURES; SPAIN; SURVIVAL;

CARDIAC MYOSINS; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; MYOSIN HEAVY CHAINS; PEDIGREE; PHENOTYPE; PROGNOSIS; SPAIN; SURVIVAL ANALYSIS;

EID: 84936747987     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-307205     Document Type: Article

References (14)

1. Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992;326:1108-14.
2. Anan R, Greve G, Thierfelder L, et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest 1994;93:280-5.
3. Coviello DA, Maron BJ, Spirito P, et al. Clinical features of hypertrophic cardiomyopathy caused by mutation of a "hot spot" in the alpha-tropomyosin gene. J Am Coll Cardiol 1997;29:635-40.
4. Moolman JC, Corfield VA, Posen B, et al. Sudden death due to troponin T mutations. J Am Coll Cardiol 1997;29:549-55.
5. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-18.
6. Woo A, Rakowski H, Liew JC, et al. Mutations of the beta myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis. Heart 2003;89:1179-85.
7. Köhler J, Winkler G, Schulte I, et al. Mutation of the myosin converter domain alters cross-bridge elasticity. Proc Natl Acad Sci USA 2002;99:3557-62.
8. McKenna WJ, Spirito P, Desnos M, et al. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 1997;77:130-2.
9. Maron BJ, McKenna WJ, Danielson GK, et al. Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687-713.
10. Mestroni L, Maisch B, McKenna WJ, et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J 1999;20:93-102.
11. Van Driest SL, Maron BJ, Ackerman MJ. From malignant mutations to malignant domains: the continuing search for prognostic significance in the mutant genes causing hypertrophic cardiomyopathy. Heart 2004;90:7-8.
12. Fananapazir L, Epstein ND. Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations. Circulation 1994;89:22-32.
13. Landstrom AP, Ackerman MJ. Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy. Circulation 2010;122:2441-9;discussion 2450.
14. O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J 2014;35:2010-20.